We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.
ARTICLE · 27 MARCH 2018
Patenting Antibodies: Obviousness Considerations

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Contributor

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Finnegan, Henderson, Farabow, Garrett & Dunner LLP is one of the world’s largest firms focusing on...
View firm profileUnder 35 U.S.C. § 103, a claim is not patentable if the "differences between the claimed invention and prior art are such that the claimed invention as a whole would have been obvious" to a person of ordinary skill...
United StatesIntellectual Property







